Vascular devices maker TriReme Medical announced a new $18 million financing round in support of the company’s new dilation catheter pipeline and global commercial efforts.
Financing was led by Luminor Capital of Singapore and joined by new Asian investors as well as existing funders, according to a press release.
"We are thrilled to have this major support from Asia in our efforts to create a next generation of interventional devices, " president & CEO Eitan Konstantino said in prepared remarks. "We share a vision of leaving no implant behind and will continue to focus on the large Asian markets in addition to the US."
TriReme, which is headquartered in Pleasanton, Calif., and Singapore, develops, manufactures and commercializes percutaneous coronary and peripheral artery disease treatment devices, with a focus on the U.S and emerging Asian markets.
